Paradigm and AVet Health Ink Exclusive Veterinary Licensing Deal for Oral Osteoarthritis Therapy in ANZ

• Binding term sheet signed for oral PPS + COX-2 inhibitor therapy in veterinary osteoarthritis
• AVet granted exclusive rights in Australia and New Zealand, with first refusal elsewhere except the US
• Paradigm to receive up to A$1 million in development milestones and tiered royalties up to 20%
• Agreement supports early veterinary data generation alongside Paradigm’s Phase 3 human trial